Nature Biotechnology 23, 1457 - 1458 (2005)
Published online: 6 December 2005; | doi:10.1038/nbt1205-1457
Cautious industry welcome for US flu vaccine planJim Kling
Bellingham, Washington
The US government's recent raft of pre-emptive measures in favor of flu vaccine R&D and stockpiling may seem like a new window of opportunity for the biotech industry, but they won't necessarily foster innovative vaccines.
|
